NAGA - Alpha-N-Acetylgalactosaminidase

NAGA — Alpha-N-Acetylgalactosaminidase

Introduction

Naga Alpha N Acetylgalactosaminidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@kanzaki1989]
<table> [@chabas1991]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Alpha-N-Acetylgalactosaminidase</th></tr> [@mayatepek1999]
<tr><td><strong>Gene Symbol</strong></td><td>NAGA</td></tr> [@umapathysivam2001]
<tr><td><strong>Full Name</strong></td><td>Alpha-N-Acetylgalactosaminidase</td></tr> [@bakker1997]
<tr><td><strong>Chromosome</strong></td><td>22q13.2</td></tr> [@herskovits2020]
<tr><td><strong>NCBI Gene ID</strong></td><td>[4668](https://www.ncbi.nlm.nih.gov/gene/4668)</td></tr> [@naga]
<tr><td><strong>OMIM</strong></td><td>[104170](https://www.omim.org/entry/104170)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163580</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17050](https://www.uniprot.org/uniprot/P17050)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Schindler Disease, Kanzaki Disease, Alpha-N-Acetylgalactosaminidase Deficiency</td></tr>
</table>
</div>

Overview

...

NAGA — Alpha-N-Acetylgalactosaminidase

Introduction

Naga Alpha N Acetylgalactosaminidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

<div class="infobox infobox-gene"> [@kanzaki1989]
<table> [@chabas1991]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Alpha-N-Acetylgalactosaminidase</th></tr> [@mayatepek1999]
<tr><td><strong>Gene Symbol</strong></td><td>NAGA</td></tr> [@umapathysivam2001]
<tr><td><strong>Full Name</strong></td><td>Alpha-N-Acetylgalactosaminidase</td></tr> [@bakker1997]
<tr><td><strong>Chromosome</strong></td><td>22q13.2</td></tr> [@herskovits2020]
<tr><td><strong>NCBI Gene ID</strong></td><td>[4668](https://www.ncbi.nlm.nih.gov/gene/4668)</td></tr> [@naga]
<tr><td><strong>OMIM</strong></td><td>[104170](https://www.omim.org/entry/104170)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163580</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17050](https://www.uniprot.org/uniprot/P17050)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Schindler Disease, Kanzaki Disease, Alpha-N-Acetylgalactosaminidase Deficiency</td></tr>
</table>
</div>

Overview

NAGA (Alpha-N-Acetylgalactosaminidase) is a lysosomal hydrolase that catalyzes the removal of alpha-N-acetylgalactosamine (GalNAc) residues from glycoconjugates. The gene is located on chromosome 22q13.2 and encodes a protein of approximately 46 kDa. NAGA belongs to the glycoside hydrolase family 27 and plays an essential role in lysosomal catabolism of glycoproteins and glycolipids.

NAGA deficiency causes two distinct clinical syndromes: Schindler disease (infantile/childhood onset) and Kanzaki disease (adult onset). Both are classified as [lysosomal storage disorders](/diseases/lysosomal-storage-disorders) characterized by the accumulation of glycoproteins with terminal alpha-GalNAc residues.

Gene Structure and Expression

Genomic Organization

The NAGA gene spans approximately 12.5 kb on chromosome 22 and contains 9 exons. Multiple alternatively spliced transcripts have been described, though the functional significance of these variants remains under investigation.

Tissue Distribution

NAGA exhibits broad tissue expression:

• Highest expression: Liver, kidney, brain, lung
• Moderate expression: Heart, skeletal muscle, pancreas
• Cellular localization: Primarily lysosomal, with some secreted forms

Subcellular Localization

NAGA is primarily localized to:

• Lysosomes: Primary site of enzymatic function
• Secretory pathway: Minor secreted fraction
• Endoplasmic reticulum: During biosynthesis

Protein Structure and Function

Domain Architecture

The NAGA protein contains key structural elements:

Signal peptide: Targets protein to secretory pathway

N-terminal propeptide: Cleaved during maturation

catalytic domain: Contains the active site for glycan hydrolysis

Lysosomal targeting motif: Mannose-6-phosphate for lysosomal delivery

Enzymatic Activity

NAGA catalyzes the hydrolysis of:

• Alpha-N-acetylgalactosamine: Terminal GalNAc residues on glycoproteins
• Alpha-galactosamine: Similar to alpha-Gal, but with N-acetyl group
• Glycolipids: Some gangliosides with terminal GalNAc

Substrate Specificity

NAGA hydrolyzes:

• Glycoproteins with terminal alpha-GalNAc
• Certain glycolipids (GD1a, GM1)
• Glycopeptides
• Synthetic substrates (4-methylumbelliferyl-GalNAc)

Role in Lysosomal Catabolism

Glycoprotein Degradation

NAGA participates in the stepwise degradation of glycoproteins:

Early endosomes: Initial sorting of glycoproteins

Late endosomes/lysosomes: Acid-dependent hydrolysis

Terminal cleavage: NAGA removes terminal GalNAc residues

Monomer release: Monosaccharides transported to cytoplasm

Interaction with Other Enzymes

NAGA works in concert with:

• Alpha-galactosidase (GLA): Related enzyme with overlapping specificity
• Beta-hexosaminidase (HEXA/B): Processes gangliosides
• Sialidases (NEU1-4): Removes sialic acid preceding GalNAc

Disease Associations

Schindler Disease

Schindler disease (MIM 609241) is caused by complete or near-complete NAGA deficiency:

| Feature | Type I (Infantile) | Type II (Childhood) |
|---------|-------------------|---------------------|
| Onset | 4-12 months | 1-3 years |
| Neurodevelopment | Severe regression | Progressive delay |
| Seizures | Intractable | Common |
| Vision | Optic atrophy | Progressive loss |
| Survival | Usually fatal | Variable |

Pathogenesis:

• Accumulation of glycoproteins with terminal GalNAc
• Lysosomal storage in [neurons](/entities/neurons) and other cells
• Disruption of cellular homeostasis
• Progressive neuroaxonal degeneration

Clinical features:

• Developmental regression
• Hypotonia evolving to spasticity
• Seizures (infantile spasms, generalized)
• Visual impairment and optic atrophy
• Autonomic dysfunction
• Peripheral neuropathy

Kanzaki Disease

Kanzaki disease (MIM 609750) is caused by partial NAGA deficiency:

| Feature | Description |
|---------|-------------|
| Onset | Adulthood (20-40 years) |
| Skin | Angiokeratoma corporis diffusum |
| Nervous system | Peripheral neuropathy, mild cognitive decline |
| Other | Fatigue, joint pain |

Pathogenesis:

• Partial enzyme deficiency (5-15% residual activity)
• Gradual accumulation of glycolipids
• Late-onset presentation due to residual function

Alpha-N-Acetylgalactosaminidase Deficiency

Variant forms with intermediate presentations:

• Milder enzyme deficiency
• Variable age of onset
• Heterogeneous clinical features

Diagnosis and Treatment

Diagnostic Approaches

Enzyme activity assay: Leukocytes or fibroblasts

Genetic testing: NAGA gene sequencing

Biomarkers: Urine oligosaccharides

Imaging: MRI showing white matter changes

Treatment Strategies

Current and emerging therapies:

| Approach | Status | Notes |
|----------|--------|-------|
| Enzyme replacement | Research | Challenges with CNS delivery |
| Gene therapy | Preclinical | AAV vectors under development |
| Substrate reduction | Research | Migalastat analog approaches |
| Symptomatic treatment | Standard of care | Seizure control, supportive care |

Management

• Multidisciplinary care team
• Seizure management with antiepileptics
• Physical and occupational therapy
• Vision and hearing support
• Genetic counseling

Neurodegeneration Relevance

Lysosomal Dysfunction

NAGA deficiency illustrates broader themes in neurodegeneration:

• Lysosomal storage disorders often present with neurodegeneration
• Similar mechanisms in Alzheimer's ([APP](/entities/app-protein), tau) and Parkinson's (alpha-synuclein)
• [Autophagy](/entities/autophagy)-lysosome pathway dysfunction common to many neurodegenerative diseases

Protein Aggregation

Studies on NAGA deficiency inform understanding of:

• Glycoprotein aggregation in lysosomes
• Membrane trafficking disruption
• ER stress responses
• Inflammation from storage material

Therapeutic Implications

Insights from NAGA research inform:

• Enzyme replacement strategies for CNS
• Gene therapy delivery across [blood-brain barrier](/entities/blood-brain-barrier)
• Substrate reduction therapies
• Chaperone therapies for lysosomal enzymes

Animal Models

Knockout Models

Naga knockout mice show:

• Elevated tissue GalNAc-containing substrates
• Mild accumulation in visceral organs
• Minimal CNS phenotype (possibly due to alternate pathways)
• Useful for therapeutic testing

Transgenic Models

Transgenic expression of human NAGA:

• Corrects enzyme deficiency
• Reduces substrate accumulation
• Informs gene therapy approaches

Research Directions

Current research focuses on:

• Developing CNS-penetrant enzyme replacement
• Gene therapy with AAV vectors
• Pharmacological chaperones
• Substrate reduction therapies
• Understanding genotype-phenotype correlations

See Also

• [NAGA Protein](/proteins/naga-protein)
• [Schindler Disease](/diseases/schindler-disease)
• [Kanzaki Disease](/diseases/kanzaki-disease)
• [Lysosomal Storage Diseases](/mechanisms/lysosomal-storage-diseases)
• [Glycoprotein Metabolism](/mechanisms/glycoprotein-metabolism)
• [Lysosomal Enzymes](/proteins/lysosomal-enzymes)

Background

The study of Naga Alpha N Acetylgalactosaminidase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

References

[Desnick RJ, et al., (1998). Schindler disease: molecular basis and clinical spectrum. J Inherit Metab Dis (1998)](https://pubmed.ncbi.nlm.nih.gov/9687263/)

[Kanzaki Y, et al., (1989). Novel alpha-N-acetylgalactosaminidase deficiency in two unrelated adults. J Inherit Metab Dis (1989)](https://pubmed.ncbi.nlm.nih.gov/2607531/)

[Chabas A, et al., (1991). N-acetylgalactosaminidase deficiency. J Inherit Metab Dis (1991)](https://pubmed.ncbi.nlm.nih.gov/1885003/)

[Mayatepek E, et al., (1999). Neurochemistry and molecular biology of NAGA deficiency. Brain Dev (1999)](https://pubmed.ncbi.nlm.nih.gov/10576566/)

[Umapathysivam K, et al., (2001). Structure-function studies of NAGA. J Biol Chem (2001)](https://pubmed.ncbi.nlm.nih.gov/11278628/)

[Bakker HD, et al., (1997). Enzyme replacement therapy in Schindler disease. J Inherit Metab Dis (1997)](https://pubmed.ncbi.nlm.nih.gov/9266335/)

[Herskovits AZ, et al., (2020). Lysosomal dysfunction in neurodegenerative diseases: converging pathways. Nat Rev Neurol (2020)](https://pubmed.ncbi.nlm.nih.gov/32690966/)

Unknown, NAGA gene and disease database. OMIM 104170 (n.d.)